In bladder cancer, it was shown that up to 40% of cases had genetic alterations in components of the PI3K/AKT/mTOR pathway, including PTEN deletions and activating mutations for TSC-1, PIK3CA, and AKT. The gene discussed is AKT1; the disease is urinary bladder carcinoma.